Feld Entertainment et un h^opital de soins primaires pour enfants annoncent un effort de financement pour une nouvelle 'etude sur le cancer

ELLENTON, Floride--(BUSINESS WIRE)--La famille Feld, propri etaires de Feld Entertainment, Inc., la soci et e m`ere de Ringling Bros. Chloromycetin (Chloramphenicol) and Barnum & Bailey® et de Ringling Bros. Tegretol (Carbamazepine) without prescription Center for Elephant Conservation®, a annonc e aujourd hui un nouvel effort de financement men e avec l Intermountain Primary Children’s Hospital (PCH) et l oncologue du D epartement de p ediatrie de l Universit e de l Utah et chercheur du Huntsman Cancer Institute, le Dr Joshua Schiffman. Dramamine (Dimenhydrinate) without Rx L engagement de financement survient apr`es la publication de nouveaux r esultats de recherche sur le cancer p ediatrique dans le Journal of the American Medical Association (JAMA) par le Dr Schiffman. Le Dr Schiffman et l equipe du Primary Children s Hospital, du D epartement de p ediatrie, et du Huntsman Cancer Institute, tous bas es `a Salt Lake City, en Utah, etudient pourquoi il y a une si faible incidence de cancer chez les el ephants, ce qui rend cette r esistance au cancer possible chez les el ephants et pas chez les humains, et comment cela peut conduire `a de nouveaux traitements pour les cancers p ediatriques. Plus de 16 000 enfants et adolescents recoivent un diagnostic de cancer chaque ann ee aux Etats-Unis alors que les el ephants ne connaissent presque pas de cancer au cours de leur vie. Genteal without prescription Le Dr Schiffman ; le Dr Dennis Schmitt, pr esident des services v et erinaires et directeur de la recherche chez Ringling Bros. About Eulexin (Flutamide) without prescription and Barnum & Bailey ; et le Dr Wendy Kiso, sp ecialiste de la recherche et de la conservation chez Ringling Bros. Buy Essential Fatty Acids online Center for Elephant Conservation ; et d autres collaborateurs scientifiques de leur equipe ; ont r ecemment confirm e que les el ephants d eveloppent rarement un cancer et affichent un taux de mortalit e de moins de 5 % alors que ce taux atteint jusqu `a 25 % chez les humains. http://webmd-help.blogspot.com En examinant le g enome de l el ephant, ils ont constat e que les el ephants affichent 40 copies d un g`ene suppresseur de tumeur appel e TP53 comparativement `a seulement deux copies chez les humains. Travaillant avec le zoo Hogle de l Utah et le Ringling Bros. Center for Elephant Conservation, le Dr Schiffman et ses coll`egues ont etudi e la r eponse du sang de l el ephant `a des agents endommageant l ADN et ont d ecouvert que les cellules d el ephants subissent une mort cellulaire plus rapidement que les cellules humaines. Le Dr Schiffman croit que cela explique pourquoi les el ephants d eveloppent moins de cancer que les humains. Les r esultats complets de l etude ont et e publi es dans la nouvelle edition du Journal of the American Medical Association. « Gr^ace `a ce partenariat entre Ringling Bros. et le Primary Children s Hospital, nous sommes en train d explorer la facon d appliquer ces d ecouvertes aux enfants et aux familles les plus `a risque de d evelopper un cancer », a d eclar e le Dr Schiffman. « Nous voulons utiliser ces lecons de la nature pour pr evenir, d evelopper des outils de d etection pr ecoce et traiter le cancer chez les humains. » L application au cancer de la recherche translationnelle (les conclusions de la science fondamentale qui favorisent la sant e humaine et le bien-^etre en am eliorant les pratiques m edicales et infirmi`eres et en cr eant des r esultats de sant e significatifs) pourrait ouvrir la voie `a une toute nouvelle fronti`ere de recherche sur le cancer et `a des traitements, allant des tests de laboratoire au chevet du patient. « Il y a vingt ans, nous avons fond e le Ringling Bros. Center for Elephant Conservation afin de pr eserver l el ephant d Asie en voie de disparition pour les g en erations futures. Nous ne savions pas alors qu ils peuvent d etenir la cl e du traitement du cancer et nous sommes ravis de faire partie de cette recherche », a ajout e Kenneth Feld, pr esident-directeur g en eral de Feld Entertainment. La famille Feld etablit le Ringling Bros. Children’s Fund™ dans le cadre de leur constante philanthropie qui vise `a soutenir, par le biais de la Fondation de la famille Feld, les organismes de bienfaisance pour enfants. Dans le cadre du partenariat avec le Primary Children s Hospital, le D epartement de p ediatrie, et le Dr Schiffman, le Ringling Bros. Children’s Fund et Ringling Bros. and Barnum & Bailey feront don de plus de 1 million USD pour soutenir la recherche sur le cancer et la prise en charge des enfants. Dans les 50 prochaines villes que Ringling Bros. and Barnum & Bailey va visiter, Ringling Bros fera un don de 10 000 USD `a un h^opital pour enfants ou `a un centre de traitement local et le Ringling Bros. Children’s Fund versera un don equivalent de 10 000 USD `a la Primary Children s Hospital Foundation afin de soutenir le Programme PCH de recherche sur le cancer p ediatrique. Ce programme, qui a permis de soutenir la recherche sur l el ephant, se concentre sur de nouvelles approches en mati`ere de pr evention, de diagnostic et d am elioration des traitements contre le cancer p ediatrique. « Chez Ringling Bros., nous nous engageons `a divertir les familles et `a partager avec les collectivit es o`u nous nous produisons chaque semaine. En plus des contributions financi`eres vers ees par Feld Entertainment et le Ringling Bros. Children’s Fund, nous enverrons nos artistes directement dans les h^opitaux pour y divertir les familles qui ne peuvent pas venir au spectacle », a d eclar e Alana Feld, vice-pr esidente ex ecutive de Feld Entertainment et productrice de Ringling Bros. and Barnum & Bailey. « Ce partenariat qui r ecolte constamment des fonds pour la recherche avec Ringling Bros. nous permet d aider `a mettre au point de nouveaux protocoles de traitement du cancer. Ces traitements favorisent une approche novatrice et plus int egr ee de traitement du cancer, fournissent de meilleurs r esultats dans la dur ee et soutiennent les familles gr^ace aux soins `a long terme », explique Richard Lemons, MD, PhD, directeur m edical et chef des services d h ematologie et d oncologie p ediatriques au Primary Children s Hospital. Le Dr Lemons supervise le Programme PCH de recherche sur le cancer p ediatrique. « Le cancer touche tant de familles dans ce pays, et, malheureusement, il devient de plus en plus fr equent, surtout chez les enfants. Nous esp erons que notre recherche m`enera `a de nouvelles perspectives pour am eliorer la prise en charge du cancer p ediatrique », conclut Katy Welkie, la pr esidente-directrice g en erale du Primary Children s Hospital. Des informations compl ementaires sur Ringling Bros. and Barnum & Bailey et le Ringling Bros. Center for Elephant Conservation, le partenariat et des renseignements sur la facon dont les familles peuvent faire un don `a la recherche sont disponibles en ligne aux adresses .ringling.com et .ringlingelephantcenter.com. `A propos de Feld Entertainment Feld Entertainment est le leader mondial dans la production et la pr esentation de spectacles itin erants de divertissement familial qui el`event l esprit humain et cr eent des souvenirs ind el ebiles. Chaque ann ee, 30 millions de personnes admirent ces spectacles. Les productions de Feld Entertainment, qui ont visit e `a ce jour plus de 75 pays sur six continents, affichent Ringling Bros. and Barnum & Bailey®, Monster Jam®, Monster Energy Supercross, AMSOIL Arenacross, Disney On Ice pr esent es par Stonyfield YoKids Organic Yogurt, Disney Live! Une pr esentation de Stonyfield YoKids Organic Yogurt et de Marvel Universe LIVE! Plus d informations sur Feld Entertainment sont disponibles en ligne `a l adresse .feldentertainment.com. Plus d informations sur le Ringling Bros. Center for Elephant Conservation sont disponibles `a l adresse .ringlingelephantcenter.com. `A propos du Primary Children s Hospital Le Primary Children s Hospital est le seul h^opital `a service complet pour enfants `a fournir, dans l Utah, l Idaho, le Wyoming, le Nevada et le Montana, des soins pour les enfants atteints des maux et maladies les plus complexes, y compris ceux qui ont besoin de transplantations cardiaques, h epatiques, r enales et de moelle osseuse. Le Primary Children s Hospital est le seul centre de traumatologie de niveau 1 pour patients p ediatriques dans la r egion Intermountain West. Il appartient `a Intermountain Healthcare, un syst`eme de soins de sant e sans but lucratif, et est affili e `a l Ecole de M edecine de l Universit e de l Utah, qui regroupe la recherche, la formation et l excellence th erapeutique pour fournir les meilleurs soins de sant e p ediatriques. Les dons sont administr es par la Primary Children s Hospital Foundation, un organisme de bienfaisance publique constitu e en vertu de l IRS Code 501(c)(3). La fondation soutient les objectifs de l h^opital visant `a fournir le plus haut niveau de soins p ediatriques dans une atmosph`ere d amour et d empathie. `A propos du D epartement de p ediatrie de l Universit e de l Utah Le D epartement de p ediatrie est le deuxi`eme plus grand d epartement de l Ecole de M edecine de l Universit e de l Utah et un des plus importants services p ediatriques dans le pays. Le d epartement compte 270 membres du corps professoral avec une r epartition `a peu pr`es egale entre hommes et femmes, et nous avons le plus grand nombre de professeures titularis ees dans l Ecole de M edecine. Le d epartement est compos e de 22 divisions et programmes m edicaux op erant en conjonction avec quatre activit es cl es : education, recherche, soins cliniques et programmes universitaires. Les divisions fournissent une gamme compl`ete de services de sp ecialit es et de sous-sp ecialit es p ediatriques pour les enfants dans toute la r egion Intermountain West. `A propos du Huntsman Cancer Institute de l Universit e de l Utah Le Huntsman Cancer Institute (HCI) est l un des meilleurs centres universitaires de recherche et de traitement du cancer dans le monde. Le HCI g`ere la Utah Population Database , la plus grande base de donn ees g en etiques dans le monde, avec plus de 16 millions de dossiers li es aux statistiques g en ealogiques, m edicales et vitales. Gr^ace `a ces donn ees, les chercheurs du HCI ont identifi e plusieurs g`enes qui causent le cancer, y compris les g`enes responsables du m elanome, des cancers du c^olon et du sein, et du paragangliome. Le HCl fait partie du National Comprehensive Cancer Network (une alliance des centres anticanc ereux mondiaux de premier plan forte de 26 membres) et est un Centre de soins complets contre le cancer reconnu par l Institut national du cancer. Le HCI traite les patients atteints de toutes les formes de cancer et g`ere plusieurs cliniques `a haut risque qui mettent l accent sur le m elanome et les cancers du sein, du c^olon, et du pancr eas. Pour informer les patients et le public, le HCI g`ere un Cancer Learning Center qui contient l une des plus grandes collections nationales de publications li ees au cancer. L institut doit son nom `a Jon M. Huntsman, un industriel philanthrope de l Utah, qui a surv ecu au cancer. Le texte du communiqu e issu d’une traduction ne doit d’aucune mani`ere ^etre consid er e comme officiel. La seule version du communiqu e qui fasse foi est celle du communiqu e dans sa langue d’origine. La traduction devra toujours ^etre confront ee au texte source, qui fera jurisprudence.

Replicor anuncia el inicio del reclutamiento para su estudio cl'inico de fase IIb con REP 2139-Mg o REP 2165-Mg en combinaci'on con Viread® y Pegasys® o Zadaxin® en pacientes con infecci'on por hepatitis B cr'onica HBeAg negativa

NUEVA YORK--(BUSINESS WIRE)--Replicor anuncia que el reclutamiento de pacientes est a en marcha para su segundo estudio de Fase II en pacientes cauc asicos que evaluar a la seguridad y la eficacia antiviral de REP 2139-Mg o REP 2165-Mg en combinaci on con Viread® y Pegasys® o Zadaxin® en pacientes con infecci on por hepatitis B cr onica HBeAg negativa. El dise~no del protocolo REP 401 (NCT02565719) se trata de la experiencia de Replicor con REP 2055 y REP 2139-Ca a partir de sus 4 estudios previos de Fase II en pacientes asi aticos y cauc asicos con infecci on por HBV o HBV / HDV. About Avapro (Irbesartan) with no Rx Este estudio aleatorio introducir a la formulaci on de pr oxima generaci on de REP 2139 (REP 2139-Mg) y un nuevo NAP, REP 2165 (como REP 2165-Mg). About Viagra Soft (Sildenafil Citrate) without Rx REP 2165 es una versi on de REP 2139 dise~nada para una eliminaci on del cuerpo m as r apida que en las evaluaciones precl inicas mostr o actividad antiviral similar con acumulaci on en el h igado significativamente reducida en comparaci on con REP 2139. El protocolo REP 401 que cumple con las BPM de la UE se realiza en Moldavia y constar a de 60 pacientes cauc asicos con infecci on HBV cr onica HBeAg negativa, todos ellos ser an expuestos a Viread® durante 24 semanas antes de ingresar a la fase de combinaci on del tratamiento. Buy Retin-A (Tretinoin) with no prescription 30 de estos pacientes (mientras contin uan con el tratamiento de Viread®) ser an distribuidos aleatoriamente en tres brazos experimentales: REP 2139-Mg + Pegasys® durante 48 semanas REP 2139-Mg + Zadaxin® durante 48 semanas REP 2165-Mg + Pegasys® durante 48 semanas. Los otros 30 pacientes ser an distribuidos aleatoriamente en brazos de control comparativos y recibir an, o bien Pegasys® o Zadaxin® (en ausencia de tratamiento con NAP) adem as de continuar con Viread®. Buy Foseal without prescription Todos los pacientes en los brazos de control comparativos que demuestren futilidad al tratamiento (seg un se define como < 3 de reducci on de logaritmo en HBsAg s erica a partir del nivel basal despu es de recibir tratamiento de combinaci on durante 24 semanas) ser an elegibles para cruzamiento aleatorio a un brazo experimental, y recibir an tratamiento con NAP durante 48 semanas, mientras contin uan con su tratamiento de combinaci on corriente. About Glycomet (Metformin) with free Rx La evaluaci on de seguimiento despu es de interrumpir todo el tratamiento est a planificada para despu es de las 48 semanas. Para m as informaci on, visite el sitio web de clinicaltrials.org: clinicaltrials.gov/ct2/show/NCT02565719?term=2139&rank=1 Acerca de Replicor Replicor es una empresa biofarmac eutica con los datos cl inicos sobre animales y humanos m as avanzada en el desarrollo de la cura de HBV y HDV. Buy Detox Tea online La empresa se dedica a acelerar el desarrollo de un tratamiento efectivo para los pacientes con infecci on por HBV y HBV/HDV. http://webmd-review.blogspot.com Para m as informaci on acerca de Replicor, visite nuestro sitio web .replicor.com y s iganos en Twitter, en @replicorinc. El texto original en el idioma fuente de este comunicado es la versi on oficial autorizada. Las traducciones solo se suministran como adaptaci on y deben cotejarse con el texto en el idioma fuente, que es la unica versi on del texto que tendr a un efecto legal.

Europ"aisches CHMP kommt zu positiver Einsch"atzung von Gileads Einzeltablettenregime Genvoya® (Elvitegravir, Cobicistat, Emtricitabin und Tenofoviralafenamid) f"ur die Behandlung von HIV

FOSTER CITY, Kalifornien (USA)--(BUSINESS WIRE)--Gilead Sciences, Inc. Buy Actos (Pioglitazone Hydrochloride) with free prescription (Nasdaq:GILD) hat heute bekannt gegeben, dass der Ausschuss f"ur Humanarzneimittel (Committee for Medicinal Products for Human Use, CHMP), der wissenschaftliche Ausschuss der Europ"aischen Arzneimittelagentur (European Medicines Agency, EMA) zu einer positiven Einsch"atzung des Marktzulassungantrags (Marketing Authorization Application, MAA) f"ur das in der Pr"ufphase befindliche Einzeltablettenregime Genvoya® (Elvitegravir 150 mg/Cobicistat 150 mg/Emtricitabin 200 mg/Tenofoviralafenamid (TAF) 10 mg) f"ur die Behandlung von Infektionen mit HIV-1 gekommen ist. Buy Zithromax Dispersible (Azithromycin) Die in der MAA angegebenen Daten unterst"utzen den Einsatz dieses Arzneiregimes bei nicht vorbehandelten erwachsenen und jugendlichen Personen, bei virologisch supprimierten Erwachsenen, die die Behandlungsmethode wechseln, sowie bei Erwachsenen mit leichter bis mittelschwerer Niereninsuffizienz. Die positive Empfehlung des CHMP wird jetzt von der Europ"aischen Kommission gepr"uft, bei der die Entscheidungsgewalt "uber die in den 28 Mitgliedsstaaten der Europ"aischen Union verwendeten medizinischen Produkte liegt. Buy Viagra Strong Pack-20 () with free Rx Bei einer Zulassung w"are Genvoya das erste Einzeltablettenregime von Gilead, das TAF enth"alt. TAF ist ein neuartiger, in der Erprobungsphase befindlicher NRTI (nukleosidischer reverser Transkriptasehemmer), der in klinischen Studien eine hohe antivirale Wirksamkeit bei einer zehnmal geringeren Dosis als Viread® von Gilead (Tenofovirdisoproxilfumarat, TDF) sowie verbesserte Nieren- und Knochenwerte im Labor gegen"uber TDF in Kombination mit anderen antiretroviralen Wirkstoffen ergeben hat. Die MAA f"ur Genvoya wird gest"utzt von 48-w"ochigen Daten aus zwei entscheidenden Phase-3-Studien (Studien 104 und 111), bei denen die Behandlung ihr vorrangiges Ziel der Nicht-Unterlegenheit im Vergleich zu Gileads Stribild® (Elvitegravir 150 mg/Cobicistat 150 mg/Emtricitabin 200 mg/Tenofovirdisoproxilfumarat 300 mg) bei behandlungsnaiven Patienten erreicht hat. Fluorometholone without Rx Im Rahmen der Studien ergab sich mit Genvoya im Vergleich zu Stribild eine Verbesserung der Nieren- und Knochenwerte im Labor. About Kamagra (Sildenafil Citrate) with free Rx Die MAA wird zudem gest"utzt von Daten aus weiteren Phase-3-Studien zur Bewertung des Arzneiregimes auf TAF-Basis bei erwachsenen, virologisch supprimierten Patienten, die zu Genvoya gewechselt haben, sowie bei erwachsenen Patienten mit leichter bis mittelschwerer Niereninsuffizienz. Ausser Genvoya untersucht die EMA momentan zwei weitere Arzneiregimes auf TAF-Grundlage. Buy Colic Remedies online Das erste davon ist ein Pr"ufpr"aparat mit einer festen Dosis einer Kombination aus Emtricitabin 200 mg und Tenofoviralafenamid 25 oder 10 mg (F/TAF) f"ur die Gabe in Kombination mit anderen antiretroviralen Wirkstoffen. http://pharmaceutical-journal.blogspot.com Das zweite ist ein in der Pr"ufphase befindliches, einmal t"aglich zu verabreichendes Einzeltablettenregime, das aus einer Kombination aus Emtricitabin 200 mg, Tenofoviralafenamid 25 mg und Rilpivirin 25 mg (R/F/TAF) besteht. Emtricitabin und Tenofoviralafenamid werden von Gilead Sciences, Rilpivirin wird von Janssen Sciences Ireland UC vermarktet. Letzteres ist eines der Janssen Pharmaunternehmen von Johnson & Johnson. TAF und alle Arzneiregimes auf TAF-Basis sind Pr"ufprodukte, deren Sicherheit und Wirksamkeit in der Europ"aischen Union nicht bewiesen wurde. "Uber Gilead Gilead Sciences ist ein Biopharmaunternehmen, das innovative Arzneimittel f"ur medizinische Bereiche erforscht, entwickelt und vermarktet, in denen ungedeckter Bedarf besteht. Das Unternehmen hat es sich zur Aufgabe gemacht, die Versorgung lebensbedrohlich erkrankter Patienten zu verbessern. Gilead ist in "uber 30 L"andern weltweit t"atig und hat seinen Hauptsitz in Foster City im US-Bundesstaat Kalifornien. Zukunftsgerichtete Aussagen Diese Pressemitteilung enth"alt zukunftsgerichtete Aussagen im Sinne des Private Securities Litigation Reform Act von 1995, die Risiken, Ungewissheiten und anderen Faktoren unterliegen, so auch dem Risiko, dass die EMA keine MAA f"ur Genvoya, F/TAF und/oder R/F/TAF ausgibt, und dass eine eventuelle Freigabe zur Vermarktung mit signifikanten Nutzungseinschr"ankungen verbunden sein k"onnte. Diese Risiken, Unsicherheiten und sonstigen Faktoren k"onnten dazu f"uhren, dass tats"achliche Ergebnisse wesentlich von den im Rahmen der zukunftsgerichteten Aussagen in Aussicht gestellten Resultaten abweichen. Die Leser werden darauf hingewiesen, sich nicht "uber Geb"uhr auf diese zukunftsgerichteten Aussagen zu verlassen. Einzelheiten zu diesen und weiteren Risiken sind im Quartalsbericht von Gilead auf Formblatt 10-Q f"ur das am 30. Juni 2015 zu Ende gegangene Quartal enthalten, der bei der US-B"orsenaufsichtsbeh"orde SEC eingereicht worden ist. Alle zukunftsgerichteten Aussagen beruhen auf Informationen, die Gilead gegenw"artig vorliegen, und das Unternehmen "ubernimmt keine Verpflichtung zur Aktualisierung solcher zukunftsgerichteter Aussagen. Die f"ur Europa geltenden Zusammenfassungen der Arzneimittelmerkmale (SmPCs) f"ur Stribild und Viread sind auf der EMA-Website unter .ema.europa.eu verf"ugbar. Genvoya, Stribild und Viread sind eingetragene Marken von Gilead Sciences Inc. oder verbundenen Unternehmen. Weitere Informationen zu Gilead Sciences erhalten Sie auf der Website des Unternehmens unter .gilead.com. Folgen Sie Gilead auf Twitter (@GileadSciences), oder wenden Sie sich an die Gilead-Abteilung f"ur "offentliche Angelegenheiten unter 1-800-GILEAD-5 oder 1-650-574-3000. Die Ausgangssprache, in der der Originaltext ver"offentlicht wird, ist die offizielle und autorisierte Version. "Ubersetzungen werden zur besseren Verst"andigung mitgeliefert. Nur die Sprachversion, die im Original ver"offentlicht wurde, ist rechtsg"ultig. Gleichen Sie deshalb "Ubersetzungen mit der originalen Sprachversion der Ver"offentlichung ab.

Magellan Rx Management Hosts 12th Annual Specialty Summit

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--A sold-out crowd gathered in New York City from September 1-3, 2015, where Magellan Rx Management, the pharmacy benefit management division of Magellan Health, Inc. About Zenegra (Sildenafil Citrate) with free Rx (NASDAQ: MGLN) recently hosted its 12th annual Specialty Summit. Boniva (Ibandronae Sodium) with no prescription Discussion focused on developments within the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) class of drugs, new Hepatitis C treatments and the associated costs, as well as other challenges and advancements in the management of specialty drugs. About Beloc (Metoprolol) with free prescription More than 300 representatives of health plans, employer groups, states, third party administrators, oncologists and practice managers, consultants, brokers and pharmaceutical manufacturers participated in the three-day symposium. “At Magellan Rx Management, we believe that the thoughtful debate and dialogue featured each year at our Specialty Summit drives new, innovative thinking and helps generate creative solutions to complex pharmacy challenges,” said Mostafa Kamal, chief executive officer of Magellan Rx Management. Buy Famvir with no Rx “Attendees have come to expect candid and thought-provoking panelists and presentations that help to advance the industry as a whole, and we are thrilled to host the right environment to accomplish just that.” The new PCSK9 inhibitor medications, with a cost exceeding $14,000 per patient and a target population that could grow substantially, remain a timely concern to payers. Buy Methotrexate () with no Rx Dr. Buy Canker Sores online Jorge Plutzky, director of preventive cardiology at Brigham and Women s Hospital, and a Harvard Medical School faculty member, led the discussion about PCSK9 inhibitors at the Specialty Summit. “These drugs are a completely novel therapeutic strategy and may be particularly important in individuals with high cardiovascular disease risk, including those with familial hypercholesterolemia,” Plutzky said. “Clinical outcomes data expected over the next few years will further help determine PCSK9 inhibitor use in the statin era.” The management of Hepatitis C was another timely topic discussed at this year’s Specialty Summit. http://md-opinion.blogspot.com “The new treatment regimens for Hepatitis C have brought to light the amazing advances that we have made to nearly eradicate a previously chronic and often debilitating disease,” said Dr. Munish Khaneja, EmblemHealth’s vice president of medical management and pharmacy operations. “The management of specialty drugs has also changed the way we look at pharmacy costs, elevating the need to not only include them as part of the total cost of medical care but also find novel ways to effectively manage and predict these costs.” In addition to the potential impact of the PCSK9 drugs and strategies for managing Hepatitis C, other topics covered during this year’s Specialty Summit included: The impact of biosimilars on the pharmaceutical industry and health plans. Strategies for managing medical benefit drugs. The emerging cost of orphan drugs. Magellan Rx Management is a pharmacy benefit manager that specializes in solving complex pharmacy challenges for its customers. Magellan Rx Management offers full-service capabilities, including formulary management, claims processing, specialty pharmacy management, targeted clinical solutions and home delivery service. About Magellan Health: Headquartered in Scottsdale, Ariz., Magellan Health, Inc. is a leader in managing the fastest growing, most complex areas of health, including special populations, complete pharmacy benefits and other specialty areas of healthcare. Magellan develops innovative solutions that combine advanced analytics, agile technology and clinical excellence to drive better decision making, positively impact health outcomes and optimize the cost of care for the members we serve — all within a customer-first culture. Magellan’s customers include health plans and other managed care organizations, employers, labor unions, various military and governmental agencies, third party administrators, consultants and brokers. For more information, visit MagellanHealth.com.

Letter to Orexo shareholders from CEO Nikolaj Sorensen

UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo AB (publ) (STO:ORX) informs that the CEO of Orexo, Nikolaj Sorensen, today has sent a letter to all shareholders of the company. About Uroxatral (Alfuzosin) with free prescription The letter provides an update on the commercialization of Zubsolv® and the sales progress in the U.S. About Claritin (Loratadine) without Rx market as well as a general business update. Buy Imdur (Isosorbide) with free Rx The letter is also available on the company s home page at .orexo.com. About Orexo Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for treatment of opioid dependence in the US. Buy Estraderm without prescription Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo’s unique knowledge and expertise in sublingual drug delivery. Buy Oxytrol (Oxybutynin) with no Rx R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Buy Body Wash online Orexo’s share is listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs on OTCQX (ORXOY) in the US. http://web-md.blogspot.com Orexo’s global headquarters and R&D are based in Uppsala, Sweden. .orexo.com. For information about ZUBSOLV and opioid dependence, please visit .zubsolv.com and .outthemonster.com This information was brought to you by Cision news.cision.com

Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015

DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/tb22l6/cancer_cd) has announced the addition of the "Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015" report to their offering. Pharmaceutical companies are continuously looking for better therapeutic options to effectively cure and prevent various malignancies. Buy Skelaxin (Metaxalone Mr) with free prescription Several options for cancer treatment are available belonging to various classes of molecules. About Diflucan (Fluconazole) with free prescription Different types of cancer have different pathophysiological characteristics due to which distinctive approach is required for effective treatment. About Sumycin (Tetracycline) Several molecules have been discovered out of which CD antigens have been found to play an important role in cancer progression and proliferation. Enapril without prescription Investigators are trying to assign different functions to CD antigens by doing extensive research and development. Prograf (Tacrolimus) with no prescription Their role in cancer development has been noted due to which lots of progress would be observed in this segment. Buy Bacopin online Most of the work has been done in cancer segment and pharmacological profiles are expected to be improved in coming years. CD antigen cancer therapeutics have diverse design and target due to which they could be used for several malignancies. http://anti-infectives-opinion.blogspot.com Presence of BiTEs, ADC, monoclonal antibodies and tri-functional antibodies for targeting different CD antigens has been commercialized. Next step is assumed to be the improvement in design as complexity at molecular levels makes it difficult to manufacture them in large quantities. This issue not only decreases the productivity but also increases the cost of production. Higher cost of end products limits the number of cancer patients choosing them as a part of their regular therapeutic regime. With the use of advanced technology it is expected that this issue would be overcome in coming years. Some of the progress could be observed in case of monoclonal antibodies and same scenario could be observed for other CD antigen cancer therapeutics in coming years. Clinical trials are being instigated across the globe in order to extend their utilities in different malignancies. They are versatile in nature due to which they could be used as a part of combinatorial therapy along with monoclonal antibodies. Their utilities in different malignancies are also being studied but results of such clinical trials remains elusive. They have strong clinical pipeline due to which several products would be introduced in coming years. However, these products are at different stages of clinical pipeline and they may take long winding times as lots of experiments proving their safety and efficacy has to be done. With time more CD antigens are expected to be discovered and they would help in the increased market size. Commercial success of marketed CD antigen cancer therapeutics shows that they would be generating significant revenues in coming years. CD antigen cancer market is expected to witness introduction of several products which will help the pharmaceutical companies to generate significant revenues. Increasing demand for better therapeutics, large unmet medical necessities and large numbers of cancer patient s patient are expected to be responsible for the growth of this market segment. Increased funding in research and development along with utilization of advanced technology will also help in increasing their market shares across the globe. Numerous innovative CD antigen cancer therapeutics are at different stages of clinical trials which would increase their market shares. Despite these facts they have higher prices and their manufacturing is difficult but utilization of advanced technology along with streamlining of various processes are expected to overcome this barrier. In this way, future of CD antigen cancer therapeutics looks optimistic due to their superior pharmacological profiles. CD Antigens Segments in Report: CD3, CD4, CD9, CD11, CD19, CD20, CD22, CD26, CD27, CD28, CD29, CD33, CD37, CD40, CD44, CD45, CD47, CD52, CD55, CD56, CD66, CD70, CD74, CD80, CD95, CD98, CD100, CD117, CD135, CD137, CD152, CD200, CD223, CD227, CD246, CD248, CD274, CD276, CD279 Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015 Report Highlight: - Nomenclature & Classification of CD Antigens - Mechanism of CD Antigen Cancer Therapeutics - Cancer CD Antigen Therapy Market Overview - Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase - Cancer CD Antigen Inhibitors Clinical Pipeline: 207 Drugs - Marketed Cancer CD Antigen Inhibitors: 27 Drugs - Majority of Cancer CD Antigen Inhibitors in Preclinical Phase: 70 Drugs - Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 44 Drugs - Cancer CD Antigens Clinical Pipeline is Represented in 52 Graphs & Charts Companies Mentioned - ARIAD Pharmaceuticals - AXXO - Alexion Pharmaceuticals - AryoGen Biopharma - Bayer HealthCare - Biocad - Biogen - Biotecnol Inc. - Bristol-Myers Squibb - Chugai Pharmaceutical - Dr Reddy s Laboratories - Eisai Co Ltd - Emergent BioSolutions - Genmab - ImmunoGen - Intas Biopharmaceuticals - MacroGenics - MedImmune - Merck - Novartis - Ono Pharmaceutical - Onyx Pharmaceuticals - PROBIOMED - Pfizer - Roche - UCB - Xencor For more information visit .researchandmarkets.com/research/tb22l6/cancer_cd

CHMP recommends label update for Giotrif® with addition of data demonstrating overall survival benefit for patients with EGFR mutation-positive lung cancer

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for an update to the European label for Giotrif® (afatinib*), strengthening and broadening the efficacy profile based on additional Phase III data. About Rheumatrex (Methotrexate) with free prescription The CHMP recommendation includes data from the LUX-Lung 3 and 6 trials which showed patients whose tumours have the most common EGFR mutation (deletion in exon 19; del19) lived more than one year longer when treated with first-line Giotrif® compared to standard chemotherapy (overall survival; OS = secondary endpoint, progression-free survival; PFS = primary endpoint). Dr. Elocon (Mometasone) without prescription Mehdi Shahidi, Medical Head, Solid Tumour Oncology, Boehringer Ingelheim commented, “This update to the European label reinforces the importance of Giotrif® as a targeted treatment for patients with EGFR mutation-positive NSCLC, especially for those whose tumours harbor the most common mutation, del19. About Macrobid (nitrofurantoin monohydrate) with no Rx Giotrif® is the first and only targeted agent to date to have shown an overall survival benefit for these patients in the first-line setting.” Following CHMP positive opinion, the European prescribing information will now be updated to include additional data from LUX-Lung 3 and LUX-Lung 6. Eldepryl with no Rx Both studies met the primary endpoint of PFS for patients whose tumours have common EGFR mutations receiving first-line Giotrif®. Retin-A (Tretinoin) with free prescription In addition to new OS data, updated PFS data from the two trials will also be reflected in the updated European label, as will the significant improvements in lung cancer-related symptoms (cough, shortness of breath, pain) and quality of life observed with Giotrif® compared to chemotherapy. Adverse events for Giotrif® in the LUX-Lung 3 and 6 trials were as expected with EGFR inhibition and were predictable, manageable and reversible. Buy Appetite Suppressants online Diarrhoea and rash/acne were the most frequently reported side effects with Giotrif® therapy. NSCLC is the most common form of lung cancer comprising over 85% of lung cancer cases. http://cardiobloodreview.wordpress.com EGFR mutation-positive NSCLC is a subtype of lung cancer. EGFR mutations are found in 10-15% of Caucasian and 40% of Asian patients with NSCLC. There are different types of EGFR mutations; the most common, which account for 90% of all EGFR mutations being del19 (approx. 50%) and L858R (approx. 40%). Afatinib, an oral, once daily ErbB family blocker, is currently approved in more than 60 countries for the first-line treatment of specific types of EGFR mutation-positive NSCLC (under brand names: Giotrif® / Gilotrif®). *Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF® and in the US under the brand name GILOTRIF® for use in patients with specific types of EGFR mutation-positive NSCLC. Registration conditions differ internationally, please refer to locally approved prescribing information. Afatinib is under regulatory review by health authorities in other countries worldwide. Afatinib is not approved in other indications. For notes to editors and references, please visit: .boehringer-ingelheim.com/news/news_releases/press_releases/2015/19_august_2015_oncology.html Intended audiences: This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business. Further Media Channels .facebook.com/boehringeringelheim .twitter.com/Boehringer .youtube.com/user/boehringeringelheim

China Ribonucleic Acid II (RNAII) for Injection Market Investigation Report 2010-2019

. About Suprax (Cefixime) without Rx DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/bxl5pl/investigation) has announced the addition of the "Investigation Report on China s ribonucleic acid II (RNAII) for Injection, 2010-2019" report to their offering. RNAII for injection, one kind of immunomodulator, can improve body immunity and inhibit tumor by causing vacuolar degeneration and colliquative necrosis in tumor cells as well as generating large amounts of hyperplastic fibroblasts, macrophages, lymphocytes or even connective tissue to substitute tumor tissue. Buy Weight Loss online About Noroxin (Norfloxacin) with no prescription And it is used for the adjuvant treatment of pancreatic cancer, liver cancer, stomach cancer, breast cancer, soft tissue sarcoma and other cancers especially hepatitis B. http://allegra-opinion.blogspot.com About Isordil Sublingual (Isosorbide Dinitrate) with no Rx RNAII for injection can also be used for the treatment of various diseases caused by low immune function. According to the market survey, RNAII for injection develops fast in China with sales value rising from less than CNY 60 million in 2005 to about CNY 500 million in 2014 and CAGR during this period reaching 80%. With the lifestyle changes brought about by economic development as well as the serious environmental pollution, the incidence of cancer keeps increasing with the number of new cases exceeding 3 million each year in China. Cycrin (Medroxyprogesterone ) with no prescription Meanwhile, there are over 90 million hepatitis B patients in China too. Dovonex without prescription Therefore, the market size of RNAII for injection is expected to keep growing in the next few years in China. Key Topics Covered: 1 Related Concepts of RNAII for Injection 2 Market Profile of RNAII for Injection in China 3 Survey on Sales Status of RNAII for Injection in China, 2010-2014 4 Survey on Market Share of Major Manufacturers of RNAII for Injection in China, 2010-2014 5 Survey on Dosage Forms of RNAII for Injection in China, 2010-2014 6 Reference Price of RNAII for Injection in Chinese Hospitals in 2014 7 Major Manufacturers of RNAII for Injection in Chinese Market, 2010-2014 8 Market Outlook of RNAII for Injection in China, 2015-2019 Companies Mentioned - Jilin Aodong Pharmaceutical Industry Group Yanji Co., Ltd - Nanjing Xinbai Pharmaceutical Co., Ltd - Xinxiang Dongsheng Pharmaceutical Co., Ltd For more information visit .researchandmarkets.com/research/bxl5pl/investigation

Pharmaceutical Packaging Market by Packaging Type, Raw Material & Drug Delivery Type - Forecasts to 2020

DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/f5jr4g/pharmaceutical) has announced the addition of the "Pharmaceutical Packaging Market by Packaging Type, by Raw Material, by Drug Delivery Type by Region (North America, Europe, Asia-Pacific, RoW) - Forecasts to 2020" report to their offering. The global pharmaceutical packaging market demand, by value is estimated to reach above $80 Billion by 2020 The pharmaceutical packaging market is anticipated to show a steady growth rate in the coming years. Moduretic (Amiloride-Hydrochlorothiazide) with free Rx Drug delivery types such as oral, pulmonary, transdermal, injectable, topical, nasal, ocular, and IV drugs, and are predicted to show higher growth than other applications. Advancement in drug delivery technologies is leading to the use of innovative packaging in many pharmaceutical sub segments. Lasix (Furosemide) This is also increasing the demand for different types of packaging materials. Arimidex (Anastrozole) with no prescription Aging of world population and rising health awareness among consumers are some of the significant drivers of the pharmaceutical market. Diurin with free prescription Rapid growth of the pharmaceutical industry globally, especially in the emerging regions along with the growing demand for drug delivery devices & blister packaging are the most important drivers of the market. About Theo-24 Sr (Theophylline ) without Rx Growth in the demand for primary packaging and rapidly increasing third party logistics also provide ample opportunity for the growth of the pharmaceutical packaging market. Buy Vitamin B5 - Pantothenic Acid online Increasing overall packaging cost along with stricter health regulations and compliance standards are hindering the growth of the market. North America and Europe are the leading regions for the consumption of pharmaceutical packaging materials. http://doctor-answers.blogspot.com/ The U.S. holds the largest share in the North American market while Germany holds the largest share in the European market. Asia-Pacific and the RoW regions are showing a significant increase in demand of pharmaceutical packaging materials. Pharmaceutical packaging companies focus keenly on research and development to provide innovative and high quality solutions to its customers. Besides, these companies also aggressively expanded, collaborated and venture with companies to increase their presence in different regions. These two are the major strategies adopted by the companies to strengthen their position in the pharmaceutical packaging market. The current scenario in the global pharmaceutical packaging market is dominated by number of major players that include MeadWestvaco Corporation (U.S.), Schott AG (Germany), Amcor Ltd. (Australia), Rexam PLC (U.K.), Gerresheimer AG (Germany), and so on. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Market Overview 5 Premium Insight 6 Market Dynamics 7 Pharmaceutical Packaging Market, By Packaging Type 8 Pharmaceutical Packaging Market, By Packaging Material 9 Pharmaceutical Packaging Market, By Drug Delivery Type 10 Pharmaceutical Packaging Market, By Geography 11 Packaging Market for Veterinary Vaccines 12 Competitive Landscape 13 Company Profiles - Amcor - Aptargroup, Inc. - Becton, Dickinson & Company - Capsugel Inc. - CCL Industries Inc. - Clondalkin - Datwyler Holding Inc. - Gerresheimer AG - Global Closure Systems Ltd - Intrapac - Klockner Pentaplast Group - Meadwestvaco Corporation - NYPRO Inc. - Rexam - RPC Group PLC - Schott - Steripack Limited - Vitro, S.A.B. De C.V. - Welch Packaging - West Pharmaceutical Services, Inc. - Wipak - Wihuri Group For more information visit .researchandmarkets.com/research/f5jr4g/pharmaceutical

Takeda apresenta Solicitac~ao de Aprovac~ao de Novo F'armaco para o Ixazomibe para Pacientes com Mieloma M'ultiplo Refrat'ario/Recidivante

CAMBRIDGE, Massachusetts e OSAKA, Jap~ao--(BUSINESS WIRE)--A Takeda Pharmaceutical Company Limited (TSE: 4502) anunciou hoje a apresentac~ao de uma Solicitac~ao de Aprovac~ao de Novo F armaco (New Drug Application - NDA) ao org~ao americano Food and Drug Administration (FDA) para o ixazomibe, um inibidor de proteassoma oral em investigac~ao, para o tratamento de pacientes com mieloma m ultiplo refrat ario e/ou recidivante. A apresentac~ao da NDA foi baseada no ensaio cl inico central de Fase 3 TOURMALINE-MM1, um estudo cl inico internacional, randomizado, duplo-cego, controlado por placebo com 722 pacientes destinado a avaliar a superioridade do ixazomibe em combinac~ao com lenalidomida e dexametasona sobre placebo combinado com lenalidomida e dexametasona em pacientes adultos com mieloma m ultiplo refrat ario e/ou recidivante. About Intagra (Sildenafil Citrate) with free prescription Os pacientes continuam a ser tratados neste ensaio e avaliados quanto aos desfechos no longo prazo. “O estudo TOURMALINE-MM1 e o primeiro de uma s erie de cinco estudos da fase 3 dentro do nosso programa ixazomibe, que foi criado para avaliar se a terapia sustentada com um inibidor de proteassoma, administrado por via oral, melhora os desfechos cl inicos de pacientes com mieloma m ultiplo ou com amiloidose sist^emica de cadeia leve (amiloidose AL)”, disse Andrew Plump, m edico, Ph.D., Diretor M edico e Cient ifico da Takeda. Buy Nizoral (Ketoconazole) with free prescription “Esta solicitac~ao de aprovac~ao assinala um passo importante no constante compromisso da Takeda com a inovac~ao para pacientes com mieloma m ultiplo. About Viagra Super Active (Sildenafil Citrate) without Rx Agradecemos aos pacientes e suas fam ilias por confiarem em n os e no ixazomibe ao continuarem a participar do programa TOURMALINE.” “O tratamento cont inuo est a emergindo como um padr~ao de tratamento do mieloma m ultiplo com melhoras comprov aveis nos desfechos de longo prazo”, comentou Paul Richardson, m edico, L ider do Programa Cl inico e Diretor de Pesquisa Cl inica do Jerome Lipper Myeloma Center, m edico do Dana-Farber Cancer Institute. Deworm with free prescription “A inibic~ao de proteassoma tornou-se um componente essencial do tratamento, mas h a desafios log isticos para os pacientes tanto nas abordagens intravenosas quanto nas subcut^aneas, especialmente na aus^encia de uma opc~ao por via oral eficaz. Viramune (Nevirapine) with free prescription Se aprovado, o ixazomibe, com a conveni^encia da administrac~ao oral uma vez por semana e a promissora efic acia, deve proporcionar um avanco muito significativo para nossos pacientes.” Essa e a primeira solicitac~ao de aprovac~ao a uma ag^encia reguladora para o ixazomibe. Buy Stress online Outras solicitac~oes de aprovac~ao est~ao previstas para comecar na Europa e em outros pa ises ainda neste ano. Sobre o Mieloma M ultiploO mieloma m ultiplo e um c^ancer das c elulas plasm aticas que se encontram na medula ossea. http://doctoranswers.wordpress.com No mieloma m ultiplo, um grupo de c elulas plasm aticas, ou c elulas de mieloma, tornam-se cancerosas e se multiplicam, elevando o n umero de c elulas plasm aticas para um n ivel superior ao normal. Como as c elulas plasm aticas circulam amplamente no corpo, elas podem afetar muitos ossos e levar a fraturas por compress~ao, les~oes osseas l iticas e dor relacionada. O mieloma m ultiplo pode causar diversos problemas de sa ude graves que afetam os ossos, o sistema imunol ogico, os rins e a contagem dos gl obulos vermelhos de uma pessoa, com alguns dos sintomas mais comuns incluindo dor ossea e fadiga, que e um sinal de anemia. O mieloma m ultiplo e uma forma rara de c^ancer com cerca de 20.000 novos casos por ano nos EUA e 114.000 novos casos por ano em todo o mundo. Sobre o IxazomibeO ixazomibe (MLN9708) e um inibidor de proteassoma oral em investigac~ao que est a sendo estudado no mieloma m ultiplo, amiloidose AL e outras doencas malignas. O ixazomibe recebeu a designac~ao de medicamento orf~ao para tratamento do mieloma m ultiplo, tanto nos EUA quanto na Europa, em 2011 e para amiloidose AL, tanto nos EUA quanto na Europa, em 2012. O ixazomibe recebeu o status de Terapia Inovadora (Breakthrough Therapy) do U.S. Food and Drug Administration (FDA) para amiloidose AL refrat aria ou recidivante em 2014. Ele tamb em e o primeiro inibidor de proteassoma oral a entrar em ensaios cl inicos de Fase 3. O programa de desenvolvimento cl inico do ixazomibe reforca ainda mais o cont inuo compromisso da Takeda com o desenvolvimento de terapias inovadoras para pessoas que vivem com mieloma m ultiplo em todo o mundo e com os profissionais de sa ude que os tratam. H a cinco ensaios cl inicos globais de Fase 3 em andamento: TOURMALINE-MM1, que investiga o ixazomibe versus placebo, em combinac~ao com lenalidomida e dexametasona em mieloma m ultiplo refrat ario e/ou recidivante TOURMALINE-MM2, que investiga o ixazomibe versus placebo, em combinac~ao com lenalidomida e dexametasona em pacientes com mieloma m ultiplo diagnosticado recentemente TOURMALINE-MM3, que investiga o ixazomibe versus placebo como terapia de manutenc~ao em pacientes com mieloma m ultiplo diagnosticado recentemente ap os terapia de induc~ao e transplante de c elulas-tronco aut ologas (ASCT) TOURMALINE-MM4, que investiga o ixazomibe versus placebo como terapia de manutenc~ao em pacientes com mieloma m ultiplo diagnosticado recentemente que n~ao foram submetidos ao ASCT TOURMALINE-AL1, que investiga o ixazomibe mais dexametasona versus regime escolhido pelo m edico dentre regimes selecionados em pacientes com amiloidose AL refrat aria ou recidivante Para informac~oes adicionais sobre os estudos de Fase 3 em andamento, acesse .clinicaltrials.gov. Sobre a Takeda OncologyA Takeda Oncology e uma unidade de neg ocios global da Millennium Pharmaceuticals Inc., uma subsidi aria integral da Takeda Pharmaceutical Company Limited. A Takeda aspira a curar o c^ancer atrav es da apresentac~ao de novos medicamentos para atender `as necessidades exclusivas e urgentes das pessoas com c^ancer, seus entes queridos e prestadores de atenc~ao `a sa ude que os apoiam no mundo todo. Takeda e a 11a maior empresa global de oncologia com um portf olio de terapias inovadoras e um extenso pipeline de produtos em investigac~ao que t^em o potencial de melhorar significativamente os desfechos dos pacientes em diversos tipos de c^ancer. Ao combinar o poder de mentes cient ificas l ideres com o nosso esp irito agil e empreendedor e os vastos recursos de uma empresa farmac^eutica global, a Takeda Oncology est a descobrindo maneiras novas e inovadoras para melhorar o tratamento do c^ancer. Informac~oes adicionais sobre a Takeda Oncology est~ao dispon iveis em seu site, .takedaoncology.com. Sobre a TakedaLocalizada em Osaka, Jap~ao, a Takeda e uma empresa global voltada para pesquisas, com foco principal em produtos farmac^euticos. Como a maior empresa farmac^eutica do Jap~ao e uma das l ideres globais do setor, a Takeda est a empenhada em lutar por uma sa ude melhor para as pessoas em todo o mundo por meio da lideranca de inovac~oes em medicamentos. Informac~oes adicionais sobre a Takeda est~ao dispon iveis em seu site corporativo, .takeda.com. O texto no idioma original deste an uncio e a vers~ao oficial autorizada. As traduc~oes s~ao fornecidas apenas como uma facilidade e devem se referir ao texto no idioma original, que e a unica vers~ao do texto que tem efeito legal.

Pacira Pharmaceuticals Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call

PARSIPPANY, N.J.--(BUSINESS WIRE)--Pacira Pharmaceuticals, Inc. Glucotrol (Glipizide) without prescription (NASDAQ:PCRX) today announced that financial results for the company’s second quarter ended June 30, 2015 will be released before the market opens on Thursday, July 30, 2015. Buy Parlodel (Bromocriptine) with no prescription The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, July 30, 2015, at 9 a.m. Kamagra Flavored (Sildenafil Citrate) with free prescription ET. About Derma-smoothe with no Rx The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) ten minutes prior to the start of the call and providing the Conference ID 93527661. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and providing the Conference ID 93527661. About Xalatan 0.005% (Latanoprost) without Rx The replay of the call will be available for two weeks from the date of the live call. The live, listen-only webcast of the conference call can also be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. Buy Skin Conditions online A replay of the webcast will be archived on the Pacira website for two weeks following the call. About Pacira Pacira Pharmaceuticals, Inc. http://future-pharmaceuticals.blogspot.com (NASDAQ: PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at .pacira.com.

Prestige Brands Holdings, Inc. to Release Fiscal 2016 First Quarter Earnings on August 6th

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Prestige Brands Holdings, Inc. Buy Cymbalta (Duloxetine) without prescription (NYSE:PBH) today announced that it will issue its fiscal 2016 first quarter earnings release on Thursday, August 6, 2015 before the opening of the market. Seroquel (Quetiapine) with no Rx The Company will host a conference call to discuss the results that same morning at 8:30 a.m. Buy Hoodia () without prescription ET. To access the call, listeners calling from within North America may dial 877-703-6109 about 15 minutes prior to the start of the call. Cyproterone Those wishing to access the call from outside North America should dial 857-244-7308. Antabuse (Disulfiram) with no Rx The conference passcode is “prestige.” The Company will provide a live Internet webcast as well as an archived replay, which can be accessed from the Investor Relations page of prestigebrands.com. Telephonic replays will be available for two weeks following completion of the live call and can be accessed at 888-286-8010 within North America, and at 617-801-6888 from outside North America. Buy Protein online The passcode is 19469360. Prestige Brands markets and distributes brand name over-the-counter healthcare and household products throughout the U.S., Canada, Australia, and in certain other international markets. http://doctorconsult.wordpress.com Core brands include Monistat® women’s health products, Nix® lice treatments, Chloraseptic® sore throat treatments, Compound W® wart treatments, Clear Eyes® eye care products, Little Remedies® pediatric products, The Doctor’s® NightGuard® dental protector, Efferdent® denture care products, Luden’s® throat drops, Dramamine® motion sickness treatments, BC® and Goody’s® headache remedies, Beano® gas prevention, Debrox® earwax remover, and in Canada, Gaviscon® antacid.

Nixon and Obama health care similarities illustrate party differences

President Obama s Affordable Care Act has been labeled "a radical liberal plan" and "socialized medicine" by Republican opposition. Buy Cymbalta (Duloxetine) without prescription Yet the roles were reversed in the early 1970s when President Nixon proposed his health plans. Seroquel (Quetiapine) with no Rx A new article in Pediatrics compares the proposals of both presidents and how opposition responded to them. The authors of the article compare the rhetoric and the reality behind the health care proposals of Republican President Richard Nixon and Democrat President Barack Obama. While many would hesitate to draw similarities between Nixon and Obama, the article by academics from the University of Michigan Medical School demonstrates that extent of partisan political rhetoric in health policy debates. "It s not that one is right and one is wrong," says author Dr. Buy Hoodia () without prescription Gary Freed. Cyproterone "But more that this is a chance to address the appropriate place of political rhetoric when it comes to improving public health, and the dangers of elevating blind partisanship over meaningful debate about important issues for our nation s health." The authors illustrate that had Nixon s proposals gone through, more people would have had insurance coverage than the number currently covered by the Affordable Care Act, also known as Obamacare. Nixon s initial National Health Strategy proposal in 1971 ruled that all employers would be required to provide basic health insurance to employees and that most of Medicaid for poor families would be replaced with a federal plan open to any family whose income was below a certain level. After this proposal had failed, Nixon came back in 1974 with his Comprehensive Health Insurance Plan. Antabuse (Disulfiram) with no Rx This proposal stated that all employers were required to insure full-time employees and that Medicaid would be replaced with a plan available to those unable to get employee health insurance or afford their own coverage. President Nixon explained the thinking behind his approach: "Those who need care most often get care least. Buy Protein online And even when the poor do get service, it is often second rate [...] This situation will be corrected only when the poor have sufficient purchasing power to enter the medical marketplace on equal terms with those who are more affluent." We need to put health care in a historical perspective Dr. http://doctorconsult.wordpress.com Freed believes that the US of today would be a very different country had the Nixon proposals been passed. "Instead, we had 30 more years with one-third of the population uninsured," he states. In comparison, the Affordable Care Act of 2010 ruled that employers with more than 50 employees are required to offer affordable insurance including a minimum set of benefits to most employees, or pay employees extra if they are eligible for tax credit to buy marketplace insurance. The act defines "affordable" insurance coverage as that which costs less than 9.5% of a household s income. In the 1970s, the Democrats declared that Nixon s proposals did not go far enough and instead offered a health proposal that the authors of the article consider far more liberal than anything the party has suggested in recent years. It appears these changing perspectives are more indicative of the two parties opposition toward each other than what they stand for in terms of health care. Positions can change over time, but it appears as though the Democrats and Republicans are inflexible when it comes to their disagreements. "We need to put health care in a historical perspective, and not go to extremes for political purposes," Dr. Freed concludes. "I would hope this history will help policy makers think about what the policy is trying to accomplish for the American people, and not turn a blind eye to proposals simply because they re proposed by one party or the other." Last year, Medical News Today reported on a study investigating state-specific difference in Medicaid provision that found cancer screening could be affected by different reimbursement and eligibility policies. Written by James McIntosh

Recovering female stroke victims may benefit from uric acid

A new study has discovered 42% of female stroke patients treated with uric acid had little to no disability compared with 29% treated with a placebo. A blood clot forming in the carotid artery. Buy Clomid (Clomiphene) with free Rx Image credit: American Heart Association A stroke is a life-changing event, impacting on an individual s psychological and physical well-being. Sumycin (Tetracycline) with free prescription Rehabilitation for recovering stroke victims is a crucial step for which many recovering patients struggle. Himcolin () with free prescription In the study - published in the journal, Stroke, for the American Heart Association (AHA) - Angel Chamorro, PhD, lead author and director of Barcelona s Comprehensive Stroke Center, Hospital Clinic Chamorro, Spain, sheds further light on what is the most effective treatment. Dr. About Curam with no Rx Chamorro and her colleagues re-analyzed 2014 data based on URIC-ICTUS, a randomized double-blind trial of patients admitted to stroke centers in Spain. Buy Astelin (Azelastine) with no prescription The participants in the study were 206 women and 205 men who were all were given treatment to remove clots. Buy Phosphatidyl Serine online Half of each gender group were randomly given either 1,000 mg of uric acid therapy or a placebo administered through intravenous infusion. At the time, the results of the study interpreted the addition of uric acid therapy to neither increase the well-being of recovering stroke patients or lead to any safety concerns. However, upon re-analyzing the data, researchers found 42% of women treated with uric acid reported less disability 3 months after a stroke compared with 29% of women treated with a placebo. http://webmd-board.blogspot.com In addition, women had less dead tissue resulting from a lack of blood supply after receiving uric acid, but among men, there was essentially no difference between the uric acid treatment and the placebo. Protect tissue from free radicals In an ischemic stroke, the most common form of stroke, a clot lodges in an artery supplying oxygen to the brain. Once doctors remove the clot, oxygen is free to re-enter the brain but it also releases harmful monocles, known as free radicals, which can damage surrounding tissue. Although high levels of uric acid can lead to health problems such as kidney stones and gout, results show it can be used to counteract the dangers of free radicals. According to Dr. Chamorro, women fared better because they traditionally possess less uric acid in their bodies. In the study, women were, on average, 7 years older than men and they were more likely to have an irregular heartbeat, high pressure and other conditions. Dr. Chamorro believes results of uric acid therapy would be even more impressive when tested on young and healthier stroke victims. The findings echo a study last year that discovered uric acid to be a major intracellular antioxidant. Last year, the AHA reported 795,000 Americans suffer from a new or recurrent stroke every year. About 55,000 more women suffer strokes than men in the US, with 60% of stroke deaths occurring in women. In response, guidelines for the prevention of stroke in women were created for the first time. Written by Peter Lam

New chemotherapy light technique discovered

Researchers have successfully pioneered a new technique that utilizes light to active chemotherapy drugs in specific cells, increasing the effectiveness of cancer therapies. About Artane (Trihexyphenidyl) with free Rx The team describes its findings in the journal Cell. Cancer cells can now be specifically targeted by light. Viagra Super Force (Sildenafil Citrate + Dapoxetine) with no prescription Image credit: Malgorzata Borowiak, LMU Munich The research co-authored by Oliver Thorn-Seshold, PhD, and Prof. About Zyloprim (Allopurinol) with free Rx Dirk Trauner, both from the Ludwig-Maximilians-Universitat, Munich, Germany. Buy Coapprovel They sought to solve the problem of the severe side effects experienced by some users of widely prescribed chemotherapeutic drugs. There are currently over 100 types of cancer currently identified, each classified by the cell that is affected. Cialis Black (Tadalafil) without prescription Different types of cancer very rarely behave similarly, hence the huge challenge facing patients and health care professionals to identify the best treatment. Buy Nasal Spray online Traditionally, chemotherapy drugs do not specifically target cancer cells, and so intersect with the function of normal cells, causing severe side effects such as heart and nerve damage. http://webmdhelp.wordpress.com Due to this risk, the treatment can only be administered in relatively low doses and does not provide the best therapeutic benefit. To overcome this challenge, scientists developed a method for optically controlling microtubule inhibitor drugs that are currently in clinical trials. Inhibitors interfere with the function of microtubules, components of the cell s skeleton that play a key role in cell proliferation, migration and survival. Researchers identified a fixed structural element required for a drug s biological activity and replaced this element with a flexible hinge that can swing open or shut in response to blue light. Prof. Trauner describes the advantage of the technique: "The upshot is that our compounds retain the powerful anticancer effects of existing microtubule inhibitors but add the bonus of tissue-specific localization." The modified compounds, called "photostatins," are effective at inhibiting the proliferation and survival of cells targeted by light, but neighboring cells are unaffected. This technique can be used numerous times, making it suitable for long-term applications in both the clinic and lab. The new development also opens the door for further research because the technique targets a critical microtubule subunit located in the cells of all plants and animals. This method may be adapted to study or treat a broad range of organisms or processes, or even potentially a broad range of diseases in humans. Truly therapeutic Dr. Thorn-Seshold hopes the elimination of the unwanted side effects ensures "the new compounds will be able to be used in medicine at dosages that are truly therapeutic in tumors, thus achieving a much more effective therapy than currently possible." In future clinical settings, scientists hope the technique can treat a range of conditions. Eye cancer patients can be treated wearing blue-tinted glasses and skin cancer with a bandage that delivers light. An implantable network of tiny LEDs that blink every few minutes to maintain the chemotherapeutic effect can be used for internal tumors. Dr. Thorn-Seshold hopes the results will be an important step in the development of cancer treatment, he said: "The field of photopharmacology is very young, so it may take some time for the pharmaceutical industry to recognize the value of compounds. Yet if our ongoing studies are successful, we will have a convincing proposition for further preclinical development, and we are committed to getting as far into real therapy as we can." Written by Peter Lam

WHO countries must raise tobacco tax to 75% of retail price

. http://webmd-magazine.blogspot.com Buy Mineral Combo online About Clarinex (Desloratadine) with no prescription Clofazimine without Rx About Xeloda (Capecitabine) without prescription Zanaflex (Tizanidine) with free Rx About Alesse (Levonorgestrel Bp + Ethinylestradiol Bp) with free Rx

Weight-loss surgery 'superior to lifestyle interventions' for type 2 diabetes

A new study suggests weight-loss surgery combined with low-level lifestyle interventions may be a more effective treatment strategy for obese patients with type 2 diabetes than lifestyle interventions alone. While lifestyle interventions alone appear to have no effect on type 2 diabetes remission, researchers found these combined with weight-loss surgery led to remission for many obese patients with the condition. Dr. About Viagra Super Fluox-Force (Sildenafil Citrate + Fluoxetine) with free prescription Anita P. About Aricept (Donepezil) Courcoulas, of the University of Pittsburgh Medical Center, PA, and colleagues publish their findings in JAMA Surgery. Excess weight is a major risk factor for type 2 diabetes; more than 90% of people who have type 2 diabetes are overweight or obese. It is recommended that obese patients with type 2 diabetes adopt lifestyle changes, such as a healthy diet and regular exercise, to help manage or treat their condition. Danocrine (Danazol) without Rx But recently, studies have suggested weight-loss surgery, or bariatric surgery, may be just as effective as lifestyle interventions and medical therapy for obese patients with type 2 diabetes In April 2014, for example, Medical News Today reported on a study published in the New England Journal of Medicine that found obese patients who underwent bariatric surgery were able to control their type 2 diabetes without the use of medical therapy in the 3 years following the procedure. But Dr. Chlorvescent with free Rx Courcoulas and colleagues say "questions remain" about the efficacy of such treatment. Buy ED Advanced Pack () without Rx "More information is needed about the longer-term effectiveness and risks of all types of bariatric surgical procedures compared with lifestyle and medical management for those with T2DM [type 2 diabetes mellitus] and obesity," they note. As such, the team assessed the outcomes of 61 obese patients aged 25-55 with type 2 diabetes who were randomly assigned to receive either weight-loss surgery in the first year followed by a low-level lifestyle intervention for 2 years, or an intense lifestyle intervention for 1 year followed by a low-level lifestyle intervention for 2 years. Subjects who underwent weight-loss surgery received one of two procedures: roux-en-Y gastric bypass (RYGB) or laparoscopic adjustable gastric banding (LAGB). Buy Ligaments - Tendons online RYGB involves the creation of a small stomach pouch from a portion of the stomach, which is then connected to the small intestine, bypassing the rest of the stomach and the duodenum. http://asthmareview.wordpress.com LAGB involves the placement of a band around the upper part of the stomach to create a smaller stomach pouch. The band can be adjusted after the procedure to make food pass more slowly or quickly through the stomach. Both of these procedures limit the amount of food a person can eat, making them feel full faster. Dr. Courcoulas and colleagues assessed the incidence of partial or complete type 2 diabetes remission among all subjects after 3 years. Weight-loss surgery led to complete type 2 diabetes remission for some obese patients Bariatric surgery was found to be most effective for weight loss among study participants. Those who underwent RYGB lost around 25% of their body weight during follow-up, LAGB subjects lost around 15% of their body weight, while lifestyle intervention-only participants lost around 5.7%. The team found that many participants who underwent weight-loss surgery followed by lifestyle interventions experienced partial or complete type 2 diabetes remission, while those who engaged in lifestyle interventions alone experienced no remission at all. Of the subjects who underwent RYGB, 40% experienced partial or complete type 2 diabetes remission, while this was the case for 29% of subjects who underwent LAGB. Three subjects treated with RYGB and one treated with LAGB had complete remission. In addition, the team found that patients who underwent weight-loss surgery were more likely to have better blood glucose control and less likely to need medication for their type 2 diabetes, compared with those who engaged in lifestyle interventions alone. "More than two thirds of those in the RYGB group and nearly half of the LAGB group did not require any medications for T2DM treatment at 3 years," say the researchers. One strength of this study, according to the team, is that around 40% of participants fell into the category of class 1 obesity - defined as having a body mass index (BMI) of between 30 and 35. The researchers note that weight-loss surgery is normally carried out on patients with a BMI of 40 or more, so data is lacking on the effects of weight-loss surgery for obese patients with a lower BMI. Commenting on their findings, the team says: "This study provides further important evidence that at longer-term follow-up of 3 years, surgical treatments, including RYGB and LAGB, are superior to lifestyle intervention alone for the remission of T2DM in obese individuals including those with a BMI between 30 and 35. While this trial provides valuable insights, unanswered questions remain such as the impact of these treatments on long-term microvascular and macrovascular complications and the precise mechanisms by which bariatric surgical procedures induce their effects." In an editorial linked to the study, Dr. Michel Gagner, of Florida International University in Miami, says the findings indicate the use of weight-loss surgery should be increased for obese individuals with type 2 diabetes. "We should consider the use of bariatric (metabolic) surgery in all severely obese patients with T2DM and start a mass treatment, similar to what was done with coronary artery bypass graft more than 50 years ago," he says. In November 2014, MNT reported on a study suggesting that weight-loss surgery may also be effective for prevention of type 2 diabetes among obese patients. Published in The Lancet Diabetes & Endocrinology, the study found that obese patients who underwent bariatric surgery were 80% less likely to develop type 2 diabetes than those who received no obesity-related treatment. Written by Honor Whiteman

Independence Day fireworks 'cause significant rise in air pollution'

July 4th has been celebrated as the birth of American independence since 1776. Zovirax (Acyclovir) without prescription Tonight, the sky will be illuminated with stunning fireworks displays that are taking place all over the US. Buy Azelex (Azelaic Acid) without prescription But according to a new study, such festivities may have an unintended consequence - a significant increase in air pollution. Fireworks set off over the US on the evening of July 4th cause an average 42% rise in air pollution, according to the researchers. Published in the journal Atmospheric Environment, the study identifies a rise in fine particulate matter, or PM2.5 - particles that are 2.5 micrometers in diameter and smaller - on the evening of July 4th and the morning of July 5th. According to the US Environmental Protection Agency (EPA), these small particles are a health concern; they can easily pass through the throat and nose to the lungs, which can trigger shortness of breath, coughing, wheezing and asthma attacks, as well as long-term health effects - such as stroke and heart attack and death from lung and heart disease. It is well known that fireworks can present health risks. About Urso (Ursodiol) with free prescription Last year, a Spotlight feature from Medical News Today noted that firework injuries - such as burns and other injuries to the hands, eyes and legs - increased by 30% compared with the previous year. According to the researchers of this latest study - including Dian J. Buy Cellmune with no Rx Seidel of the National Oceanic and Atmospheric Association (NOAA) Air Resources Laboratory in College Park, MD - previous studies had identified increases in air pollutants during and following fireworks displays. "But no study to date has explored fireworks effects on air quality over large regions using systematic observations over multiple years to estimate typical regional PM [particulate matter] increases," they note. Concentrations of fine particulate matter 42% higher on evening of July 4th Seidel and study co-author Abigail N. Buy Erythromycin (Erythromycin) without Rx Birnbaum, of the University of Maryland and student intern at NOAA, set out to address this research gap, assessing the air quality of 315 sites across the US on every 4th July between 1999 and 2013. "We chose the holiday, not to put a damper on celebrations of America s independence, but because it is the best way to do a nationwide study of the effects of fireworks on air quality," says Siedel. The researchers analyzed the hourly concentrations of fine particulate matter on the evening of July 4th, comparing them with those of the days before and after, The team found that on average, concentrations of fine particulate matter were 42% higher on the evening of July 4th, compared with the days before and after the holiday. Buy Jojoba Oil online Levels reached their highest between 9 pm and 10 pm, with increases beginning at 8 pm. http://webmd-review.blogspot.com The increases lasted until around midday on July 5th. The researchers identified variations in PM2.5 concentrations between air quality monitoring sites, which appeared to be dependent on weather conditions and how close the fireworks were to the site. For example, concentrations were around 370% higher on the evening of July 4th at one site where the fireworks were set off in a field adjacent to it - which the team says is at a level well above the maximum 24-hour limit of 35 mcg per cubic meter set by the EPA. Commenting on the findings, Seidel says: "These results will help improve air quality predictions, which currently don t account for fireworks as a source of air pollution. The study is also another wake-up call for those who may be particularly sensitive to the effects of fine particulate matter." The team notes that while the EPA do not regulate fireworks, they do recommend that individuals who are sensitive to air pollution - such as those with asthma - watch fireworks displays from a distance and ensure they have any required medication to hand. Written by Honor Whiteman